BTAI Stock Analysis: Buy, Sell, or Hold?
BTAI - BioXcel Therapeutics, Inc. Common Stock
$1.31
0.05 (3.97%)
▲
5d:
+9.17%
30d:
+15.93%
90d:
-8.39%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When BTAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BTAI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BTAI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BTAI is currently trading at $1.31, which is considered extended relative to its 30-day fair value range of $1.10 to $1.25.
Technical Outlook: Technically, BTAI is in a strong downtrend. Immediate support is located at $1.06, while resistance sits at $1.36. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: BTAI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.00 (+968.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BTAI is in a strong downtrend. Immediate support is located at $1.06, while resistance sits at $1.36. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: BTAI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.00 (+968.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.10 -
$1.25
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 968.7% below Wall St target ($14.00)
Trading Range Analysis
30-Day Trading Range
$1.10 -
$1.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.36
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.85
Wall Street Target
$14.00
(+968.7%)
Revenue Growth (YoY)
22.6%
Share & Embed Analysis
Last updated: June 24, 2026 6:51 PM ET
Data refreshes hourly during market hours. Next update: 7:51 PM
Data refreshes hourly during market hours. Next update: 7:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BTAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
